Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 50

Note*:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Global Markets Direct's, ‘Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2016', provides in depth analysis on Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted pipeline therapeutics.

The report provides comprehensive information on the Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1)

  • The report reviews Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Overview 7
Therapeutics Development 8
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Products under Development by Stage of Development 8
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Products under Development by Therapy Area 9
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Products under Development by Indication 10
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Products under Development by Companies 13
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Products under Development by Universities/Institutes 15
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Companies Involved in Therapeutics Development 24
Astraea Therapeutics, LLC 24
Grunenthal GmbH 25
Serodus ASA 26
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Drug Profiles 27
AT-076 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
AT-089 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
AT-127 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
AT-212 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
AT-326 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
AT-403 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
cebranopadol - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
GRTTA-2210 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Peptides to Agonize ORL1 for Pain - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
RO-656570 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
SER-100 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Small Molecules to Agonize NOP for Pain and Alcohol Addiction - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Dormant Projects 42
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Discontinued Products 43
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Featured News & Press Releases 44
May 23, 2016: Cebranopadol Data Presented at World Institute of Pain Congress Highlight Clinically Significant Reductions in Pain, Low Abuse Potential and a Favorable Respiratory Profile 44
Apr 18, 2016: PCT SER100 patent application filed - Serodus demonstrates a novel mechanism of action in Pulmonary Hypertension 45
Feb 29, 2016: Cebranopadol Top-Line Data From Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All Arms 45
Apr 20, 2015: Provisional patent application filed for the Orphan Diseases of Pulmonary Hypertension 46
Sep 15, 2014: Serodus announces details on the clinical study of SER100 in patients with systolic hypertension 46
Sep 09, 2014: Serodus Announces Positive Phase IIa Clinical Study Results On SER100 In Patients with Systolic Hypertension 47
Jun 23, 2014: Serodus Completes The Enrollment Of Patients In Phase IIa Study 47
Nov 05, 2013: Serodus Enrolls First Patient in SER100 Phase IIa Isolated Systolic Hypertension Clinical Study 47
Apr 03, 2013: Serodus Receives Notice Of Allowance For Canadian Patent Covering SER100 48
Jan 11, 2011: Serodus Receives Patent For SER100 In Japan 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 19
Number of Products by Stage and Route of Administration, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 23
Pipeline by Astraea Therapeutics, LLC, H2 2016 24
Pipeline by Grunenthal GmbH, H2 2016 25
Pipeline by Serodus ASA, H2 2016 26
Dormant Projects, H2 2016 42
Discontinued Products, H2 2016 43

List of Figures

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Top 10 Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Mechanism of Actions, H2 2016 18
Number of Products by Stage and Mechanism of Actions, H2 2016 19
Number of Products by Routes of Administration, H2 2016 20
Number of Products by Stage and Routes of Administration, H2 2016 20
Number of Products by Molecule Types, H2 2016 22
Number of Products by Stage and Molecule Type, H2 2016 22
  • United States Biobanking Market Report 2018
    Published: 22-Feb-2018        Price: US 3800 Onwards        Pages: 108
    In this report, the United States Biobanking market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate ......
  • Global Label-free Array Systems Market Professional Survey Report 2018
    Published: 21-Feb-2018        Price: US 3500 Onwards        Pages: 101
    This report studies Label-free Array Systems in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2013 to 2018, and forecast to 2025. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Agilent Technologies - Attana - Biacore - ForteBio -......
  • Global Prepacked Chromatography Columns Sales Market Report 2018
    Published: 20-Feb-2018        Price: US 4000 Onwards        Pages: 108
    In this report, the global Prepacked Chromatography Columns market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Prepacked Chromatography Columns for these regions, from 2013 to 2025 (forecast), covering - United States - China......
  • 2018-2025 Laser Capture Microdissection Report on Global and United States Market, Status and Forecast, by Players, Types and Applications
    Published: 20-Feb-2018        Price: US 3600 Onwards        Pages: 129
    Summary This report studies the Laser Capture Microdissection market status and outlook of global and United States, from angles of players, regions, product types and end industries; this report analyzes the top players in global and United States market, and splits the Laser Capture Microdissection market by product type and application/end industries. The global Laser Capture Microdissection market is valued at XX million USD in 2017 and is expected to reach XX m......
  • Flow Cytometry Market by Technology (Cell & Bead-based), Product & Services (Analyzer, Sorter, Reagents), Application (Research (Cell Analysis), Clinical (Cancer, HIV)), End User (Academia, Research Institute, Hospital) - Global Forecast to 2022
    Published: 20-Feb-2018        Price: US 5650 Onwards        Pages: 202
    “The global flow cytometry market is projected to grow at a CAGR of 7.8%.” The global flow cytometry market is projected to reach USD 4.79 billion by 2022 from USD 3.29 billion in 2017, growing at a CAGR of 7.8% from 2017 to 2022. The key factors driving the growth of this market include the continuous technological advancements in the field of flow cytometry, increasing incidence and prevalence of target diseases (such as HIV/AIDS and cancer), and growing......
  • C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Pipeline Review, H1 2018
    Published: 20-Feb-2018        Price: US 3500 Onwards        Pages: 60
    C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report C-X-C Chemokine Receptor Type 2 - Pipeline Review, outlays comprehensive information on the C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or ......
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H1 2018
    Published: 20-Feb-2018        Price: US 3500 Onwards        Pages: 104
    C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - C-X-C chemokine receptor type 4 or CD184 is a protein encoded by the CXCR4 gene. It is a receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation, extr......
  • Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H1 2018
    Published: 20-Feb-2018        Price: US 3500 Onwards        Pages: 46
    According to the recently published report 'Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H1 2018'; Glucagon Like Peptide 2 Receptor (GLP2R) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies. Glucagon Like Peptide 2 Receptor (GLP2R) - Glucagon-like peptide 2 receptor (GLP-2R) is a protein encoded by the GLP2R gene. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut. GLP2 st......
  • Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H1 2018
    Published: 20-Feb-2018        Price: US 3500 Onwards        Pages: 79
    Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) pipeline Target constitutes close to 25 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The latest report Metabotropic Glutamate Receptor 5 - Pipeline Review, H1 2018, outlays comprehensive information on the Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs